GlassScriptPhysician profile
Maryum Rafique
NPI 1538328869
$5,205.66
in general payments reported to CMS, 2019-2025
32 companies · $855 in 2025
The $855 reported for 2025 was more than what 86% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $711 · 2021: $635 · 2022: $386 · 2023: $589 · 2024: $1,212 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746 · Travel and Lodging: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.76 |
| Travel and Lodging | $909.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $959.45 | 2019-2025 | Eterna, Proclaim, Octrode |
| Si-Bone, INC. | $786.37 | 2024 | |
| Collegium Pharmaceutical, INC. | $509.94 | 2019-2025 | Belbuca, Xtampza |
| Biotronik Nro, INC. | $314.41 | 2025 | Prospera |
| Spr Therapeutics, INC | $311.39 | 2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.04 | 2021-2024 | Relistor |
| Scilex Pharmaceuticals INC. | $270.86 | 2019-2025 | |
| Nevro Corp. | $263.29 | 2019-2024 | Senza |
| Daiichi Sankyo INC. | $166.42 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $121.06 | 2022 | |
| Redhill Biopharma INC. | $117.38 | 2020-2022 | |
| Pfizer INC. | $105.88 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $98.80 | 2020-2023 | Austedo Xr |
| Lilly USA, LLC | $95.63 | 2020-2021 | |
| Medtronic, INC. | $84.97 | 2022-2025 | Vanta Adaptivestim, Synchromedii, Intellis Adaptivestim |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $72.12 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $71.30 | 2021 | |
| Saluda Medical Americas, INC. | $62.76 | 2025 | Evoke |
| Almatica Pharma LLC | $54.83 | 2021 | |
| Biodelivery Sciences International, INC. | $53.24 | 2019-2020 | |
| Shionogi INC | $51.55 | 2019 | |
| Abbvie INC. | $50.79 | 2023-2024 | |
| Tersera Therapeutics LLC | $49.76 | 2019-2021 | |
| Amgen INC. | $48.43 | 2021-2022 | |
| Medtronic USA, INC. | $41.21 | 2019 | |
| Grt US Holding, INC. | $35.68 | 2020-2021 | |
| Painteq LLC | $26.55 | 2024 | Painteq |
| Astrazeneca Pharmaceuticals LP | $16.95 | 2019 | |
| Boston Scientific Corporation | $16.60 | 2025 | Intracept |
| Ibsa Pharma INC. | $16.04 | 2021 | |
| Foundation Fusion Solutions, LLC | $15.62 | 2025 | |
| Globus Medical, INC. | $15.34 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryum Rafique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.